Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05338476 · ClinicalTrials.gov registry record · Phase 1

A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT05338476: Completed Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

NCT05338476 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 16 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05338476, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to assess the effect of selpercatinib on how fast midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to about 6 weeks, inclusive of screening period.

Primary Outcome

PK: PK: AUC0-t of midazolam and its metabolite 1-OH-midazolam was reported.

Conditions Studied

Healthy

Interventions

  • DRUG Midazolam
  • DRUG Selpercatinib

Study Locations (1)

Arizona

  • Celerion - Tempe

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2018-07-12
Est. Completion 2018-09-18
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT05338476 record still lists

NCT05338476 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.

NCT05338476 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT05338476 about?

NCT05338476 is a clinical study titled "A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants". The main purpose of this study is to assess the effect of selpercatinib on how fast midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to about...

What is the current status of trial NCT05338476?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-07-12. Estimated completion is 2018-09-18.

What conditions does trial NCT05338476 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT05338476?

The interventions under investigation include: Midazolam (DRUG), Selpercatinib (DRUG).

Who is sponsoring clinical trial NCT05338476?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05338476 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05338476's enrollment target sits among peer trials

16 936th of 1090 higher than 137 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05338476, the US trial registry maintained by the National Library of Medicine. NCT05338476 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.